Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves
March 2014
Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.
Farxiga (dapagliflozin) is similar to Invokana (canagliflozin).
They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote